Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

LIQ001

Vaccine · Immune activation · developed by Liquidia Technologies

Phase 1/2 Most advanced trial (none active)
LQDA Developer
1 Registered trials

What is LIQ001?

LIQ001 is a vaccine given as a single vaccination at doses of 0.45 mg or 1.8 mg. It is studied in influenza.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Vaccine
Mechanism
Immune activation
Therapy area
Infectious disease
Developer
Liquidia Technologies, Inc. (LQDA)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT01224262 Phase 1/2 Influenza Completed LQDA

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Influenza

More from Liquidia Technologies

Sources

Updated Oct 18, 2026. Something wrong or missing? Report it on the LQDA page.

Follow LQDA, the company behind LIQ001

See LQDA's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

LQDA catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.